Full Press Release Details
Chief Financial Officer
Inc. Reports Higher Fourth Quarter and Full Year Revenues and Profits
Full Year Revenue up 25%
Full Year Earnings per
Share $0.13 Compared to Loss of $0.16 in Prior Year
New Prague, Minnesota - September 15, 2015 - Electromed,
Inc. (NYSE MKT: ELMD) today announced financial results for its fourth quarter and fiscal year ending June 30, 2015.
Fourth Quarter Results
Net revenues for the fourth quarter of fiscal 2015 rose approximately
13% to $5.2 million, compared to $4.6 million in the same quarter of fiscal 2014. Growth in total net revenues was attributable
to strong results in the home care market where revenue increased by approximately 11.8%, or $0.5 million, compared to the same
period of fiscal 2014. Home care sales increased due to a greater number of approvals and a higher average selling price from third
party payers, such as insurance companies, Medicare and Medicaid, for the Company's SmartVest products. Broader
sales coverage and more focused territory management also contributed to the sales increase.
The Company reported net income of $255,000, or $0.03 cents
per basic and diluted share, for the fourth quarter of fiscal 2015, compared to $290,000, or $0.04 per basic and diluted share,
for the same period of fiscal 2014. Net income in the fourth quarter of fiscal 2015 was affected by an increase in our current
tax expenses as we fully utilized our federal net operating loss carryforwards and by a reserve on certain SV2100 inventory parts,
that may no longer be utilized in production, of $110,000, due to achieving additional cost reductions that will lower the cost
of our newer SmartVest SQL to a cost significantly lower than our previous products and that will shorten the length of time that
we phase out sales of our SV2100 product.
Gross margins in the fourth quarter of fiscal 2015 were 72.0%,
up from 70.1% in the fourth quarter of fiscal 2014. The increase in gross profit percentage resulted primarily from the increase
in domestic home care revenue at higher average selling price and greater referral to approval percentage, as compared with the
same period in the prior year. Operating expenses, which include selling, general and administrative as well as research and development
expenses, in the fourth quarter of fiscal 2015, were $3.3 million or 64.2% of revenue compared with $2.9 million or 62.3% of revenue
in the same period of the prior year. The increase was due primarily to higher sales commission expense, recruiting costs for additional
salespeople and consulting fees for sales training and information technology improvements.
Commenting on the fourth quarter results, Kathleen Skarvan,
President and Chief Executive Officer of the Company said, "We are pleased to report another solid quarter of revenue growth
and increased profitability. Execution across the Company continued to improve and we are seeing the results of our commitment
to achieving consistently higher referral to approval percentages, lower manufacturing costs and best-in-class patient service.
Our improved profitability also contributed to strong cash flow from operations of nearly $1 million in the fourth quarter and
we ended the quarter with $3.6 million in cash."
Results for the Three-and Twelve-Months
Net revenues for the fiscal year ended June 30, 2015 were $19.4
million, an increase of 25% compared with the previous year. Net income was $1.1 million, or $0.13 per basic and diluted share
compared with a net loss of $1.3 million, or $0.16 per basic and diluted share, in the previous year. The fiscal 2014 loss included
a full valuation allowance against all the Company's net U.S. federal and state deferred tax assets totaling $727,000 which
offset expected tax benefits and resulted in a tax expense of $469,000 for the year.
The higher revenue in fiscal 2015 was the result of higher sales
in both the home care and institutional markets. Home care, which accounted for about 86% of total revenue, increased 28% and institutional
rose 22% compared with fiscal 2014. The increase resulted primarily from higher approval rates on referrals, higher average selling
price and an increase in the total number of referrals. Referrals are prescriptions for our products from a physician for a patient
and the approvals are from third-party payer organizations including Medicare, Medicaid and private insurance providers.
Gross profit for fiscal 2015 was $13.6 million, or 70.1% of
net revenue, compared with 68.7% in the prior year. The increase was the result of higher net revenues and higher average selling
prices. Gross margin for 2015 was negatively impacted by a write-off and reserves for obsolete inventory and tooling. Operating
expenses were $12.3 million or 63.3% of net revenues, in fiscal 2015, compared with $11.4 million, or 73.4% of revenues, in the
prior year. The decline in expenses as a percentage of net revenues was primarily due to the higher level of revenues in fiscal
2015 as well as careful alignment of spending with opportunities. The Company expects its revenues to continue to grow faster than
expenses in fiscal 2016. Cash flow from operations was $2.8 million in fiscal 2015, compared with $2.1 million in the prior year.
Commenting on the full year results, Ms. Skarvan said, "Fiscal
2015 was an important year for Electromed as we demonstrated revenue growth year over year, achieved four profitable quarters and
delivered solid cash flow and earnings per share. The emphasis we placed on aligning the Company to compete in the current and
future healthcare environment by improving our reimbursement process, lowering manufacturing costs and upgrading sales execution
has begun to pay off. I am grateful for our dedicated team of employees for their focus on patient care and satisfaction, an essential
component of our success. Looking ahead, we believe the market for high frequency chest wall oscillation products is poised to
grow as more patients, especially older ones, are diagnosed with breathing issues for which HFCWO is a proven therapy option. We
have excellent product offerings and a strong team to take advantage of these opportunities. The Company's balance sheet
is strong and we have the financial resources in place to grow as the market unfolds."
About Electromed, Inc.
Electromed, Inc. develops, manufactures, markets, and sells
innovative products that provide airway clearance therapy, including the SmartVest Airway Clearance System and
related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. Further
information about the Company can be found at www.electromed.com.
Results for the Three-and Twelve-Months
Cautionary Statements
Certain statements found in this release may constitute forward-looking
statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect the speaker's
current views with respect to future events and financial performance and include any statement that does not directly relate to
a current or historical fact. Forward-looking statements can generally be identified by the words "anticipate," "believe,"
"expect," "will" and similar words. Forward-looking statements made in this release include the Company's
beliefs regarding continued progress in its reimbursement, revenue growth and cost control strategies, expectations for market
growth, available financial resources. Forward-looking statements cannot be guaranteed and actual results may vary materially due
to the uncertainties and risks, known and unknown, associated with such statements. Examples of risks and uncertainties for the
Company include, but are not limited to, the impact of emerging and existing competitors, the effect of new legislation on our
industry and business, the effectiveness of our sales and marketing and cost control initiatives, changes to reimbursement programs,
as well as other factors described from time to time in our reports to the Securities and Exchange Commission (including our Annual
Report on Form 10-K). Investors should not consider any list of such factors to be an exhaustive statement of all of the risks,
uncertainties or potentially inaccurate assumptions investors should take into account when making investment decisions. Shareholders
and other readers should not place undue reliance on "forward-looking statements," as such statements speak only as
of the date of this release.
Financial Tables Follow:
| June 30, | June 30, | |||||||
| 2015 | 2014 | |||||||
| Assets | ||||||||
| Current Assets | ||||||||
| Cash | $ | 3,598,240 | $ | 1,502,702 | ||||
| Accounts receivable (net of allowances for doubtful accounts of $45,000) | 6,518,816 | 6,487,267 | ||||||
| Inventories | 2,072,108 | 2,235,496 | ||||||
| Prepaid expenses and other current assets | 397,833 | 397,853 | ||||||
| Total current assets | 12,586,997 | 10,623,318 | ||||||
| Property and equipment, net | 3,635,516 | 3,935,802 | ||||||
| Finite-life intangible assets, net | 999,842 | 1,039,413 | ||||||
| Other assets assets | 182,699 | 193,633 | ||||||
| Total assets | $ | 17,405,054 | $ | 15,792,166 | ||||
| Liabilities and Shareholders' Equity | ||||||||
| Current Liabilities | ||||||||
| Current maturities of long-term debt | $ | 48,749 | $ | 46,375 | ||||
| Accounts payable | 538,518 | 380,582 | ||||||
| Accrued compensation | 700,370 | 391,040 | ||||||
| Income tax payable | 122,657 | - | ||||||
| Warranty reserve | 660,000 | 700,000 | ||||||
| Other accrued liabilities | 208,983 | 302,482 | ||||||
| Total current liabilities | 2,279,277 | 1,820,479 | ||||||
| Long-term debt, less current maturities | 1,202,446 | 1,251,192 | ||||||
| Total liabilities | 3,481,723 | 3,071,671 | ||||||
| Commitments and Contingencies | ||||||||
| Equity | ||||||||
| Common stock, $0.01 par value; authorized: 13,000,000; shares issued and outstanding: 8,133,857 and 8,114,252 at June 30, 2015, June 30, 2014, respectively | 81,339 | 81,143 | ||||||
| Additional paid-in capital | 13,327,320 | 13,217,166 | ||||||
| Retained earnings (accumulated deficit) | 514,672 | (577,814 | ) | |||||
| Total shareholders' equity | 13,923,331 | 12,720,495 | ||||||
| Total liabilities and shareholders' equity | $ | 17,405,054 | $ | 15,792,166 |
Statements of Operations
| For the Three Months Ended June 30, | For the Twelve Months Ended June 30, | |||||||||||||||
| 2015 | 2014 | 2015 | 2014 | |||||||||||||
| Net revenues | $ | 5,199,146 | $ | 4,612,286 | $ | 19,408,385 | $ | 15,487,875 | ||||||||
| Cost of revenues | 1,453,819 | 1,377,302 | 5,808,158 | 4,853,873 | ||||||||||||
| Gross profit | 3,745,327 | 3,234,984 | 13,600,227 | 10,634,002 | ||||||||||||
| Operating expenses | ||||||||||||||||
| Selling, general and administrative | 3,259,637 | 2,811,463 | 11,974,384 | 10,908,531 | ||||||||||||
| Research and development | 78,446 | 61,054 | 315,647 | 466,063 | ||||||||||||
| Total operating expenses | 3,338,083 | 2,872,517 | 12,290,031 | 11,374,594 | ||||||||||||
| Operating income (loss) | 407,244 | 362,467 | 1,310,196 | (740,592 | ) | |||||||||||
| Interest expense, net of interest income of $284, $663, $2,328 and $12,393 respectively | 20,226 | 21,011 | 85,710 | 79,002 | ||||||||||||
| Net income (loss) before income taxes | 387,018 | 341,456 | 1,224,486 | (819,594 | ) | |||||||||||
| Income tax expense | (132,000 | ) | (51,000 | ) | (132,000 | ) | (469,000 | ) | ||||||||
| Net Income (loss) | $ | 255,018 | $ | 290,456 | $ | 1,092,486 | $ | (1,288,594 | ) | |||||||
| Income (loss) per share: | ||||||||||||||||
| Basic | $ | .03 | $ | 0.04 | $ | .13 | $ | (0.16 | ) | |||||||
| Diluted | $ | .03 | $ | 0.04 | $ | .13 | $ | (0.16 | ) | |||||||
| Weighted-average common shares outstanding: | ||||||||||||||||
| Basic | 8,119,638 | 8,114,252 | 8,115,595 | 8,114,252 | ||||||||||||
| Diluted | 8,164,864 | 8,114,252 | 8,153,703 | 8,114,252 |
Condensed Statements of Cash Flows
| Years Ended June 30, | ||||||||
| 2015 | 2014 | |||||||
| Cash Flows From Operating Activities | ||||||||
| Net income (loss) | $ | 1,092,486 | $ | (1,288,594 | ) | |||
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||||||||
| Depreciation | 613,304 | 567,341 | ||||||
| Amortization of finite-life intangible assets | 122,911 | 128,205 | ||||||
| Amortization of debt issuance costs | 19,210 | 18,019 | ||||||
| Share-based compensation expense | 110,350 | 82,228 | ||||||
| Deferred income taxes | 454,000 | |||||||
| Loss on disposal of property and equipment and intangible assets | 300,530 | 138,827 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (31,549 | ) | 2,526,776 | |||||
| Inventories | 163,388 | (855,902 | ) | |||||
| Income tax receivable | - | 538,285 | ||||||
| Prepaid expenses and other assets | 6,541 | 60,288 | ||||||
| Accounts payable and accrued liabilities | 384,043 | (302,285 | ) | |||||
| Net cash provided by operating activities | 2,781,214 | 2,067,188 | ||||||
| Cash Flows From Investing Activities | ||||||||
| Expenditures for property and equipment | (523,185 | ) | (895,177 | ) | ||||
| Expenditures for finite-life intangible assets | (101,322 | ) | (45,149 | ) | ||||
| Net cash used in investing activities | (624,507 | ) | (940,326 | ) | ||||
| Cash Flows From Financing Activities | ||||||||
| Proceeds from long-term debt | - | 1,300,000 | ||||||
| Principal payments on long-term debt including capital lease obligations | (46,372 | ) | (1,392,428 | ) | ||||
| Payments of deferred financing fees | (14,797 | ) | (35,296 | ) | ||||
| Net cash used in financing activities | (61,169 | ) | (127,724 | ) | ||||
| Net increase in cash | 2,095,538 | 999,138 | ||||||
| Cash | ||||||||
| Beginning of period | 1,502,702 | 503,564 | ||||||
| End of period | $ | 3,598,240 | $ | 1,502,702 |